2024
Trends in the Use of Medications for Secondary Ischemic Stroke Prevention in Denmark, 2005-2021.
Skajaa N, Laugesen K, Lauffenburger J, Schwamm L, Sørensen H, Patorno E. Trends in the Use of Medications for Secondary Ischemic Stroke Prevention in Denmark, 2005-2021. Neurology 2024, 102: e209309. PMID: 38648572, PMCID: PMC11226314, DOI: 10.1212/wnl.0000000000209309.Peer-Reviewed Original ResearchConceptsMedication useOral anticoagulant medicationsGlucose-lowering medication useFactors associated with medication useLipid-lowering medication useSevere strokeIschemic stroke hospitalizationsAntihypertensive medication useAnticoagulant medicationOlder patientsCare of patientsSodium-glucose cotransporter-2 inhibitorsGlucagon-like peptide-1 receptor agonistsStroke preventionAnticoagulant medication useLipid-loweringPeptide-1 receptor agonistsGlucose-loweringReduced life expectancyIschemic strokeCotransporter-2 inhibitorsStroke careCohort of patientsStroke hospitalizationsSecondary ischemic stroke prevention
2020
Probing the Effective Treatment Thresholds for Alteplase in Acute Ischemic Stroke With Regression Discontinuity Designs
Naidech A, Lawlor P, Xu H, Fonarow G, Xian Y, Smith E, Schwamm L, Matsouaka R, Prabhakaran S, Marinescu I, Kording K. Probing the Effective Treatment Thresholds for Alteplase in Acute Ischemic Stroke With Regression Discontinuity Designs. Frontiers In Neurology 2020, 11: 961. PMID: 32982952, PMCID: PMC7492202, DOI: 10.3389/fneur.2020.00961.Peer-Reviewed Original ResearchTreatment thresholdOutcomes of patientsAcute ischemic strokeCohort of patientsPatient demographic characteristicsIschemic strokeControlled TrialsStroke interventionClinical outcomesClinical careEffective treatmentLarger sample sizeMedical interventionsPatientsDemographic characteristicsGold standardAlteplaseInterventionTreatmentContinuous variablesOutcomesLimited populationSample sizeTreatment timePotential reasons